Health ❯ Healthcare ❯ Clinical Trials

Efficacy Studies

Lecanemab Phase 3 Trials OASIS 4 Trial Weight Loss Efficacy Patient Outcomes Lecanemab Trials Orforglipron Lenacapavir Efficacy Obesity Treatments Hormone Receptor-Positive Cancer Drug Comparisons AUGMENT-101 Trial Weight Loss Outcomes Amycretin Trials mNEXSPIKE Vaccine Simplify-1 Study Phase IIb/III Trials TRANSCEND FL Study Beamion LUNG-1 Trial Placebo-Controlled Trials Phase-3 Trials H3 K27M Mutations Tirzepatide vs Dulaglutide FRESCO Trials LUNA 3 Study Wegovy Oral Orforglipron vs Semaglutide Cagrilintide Analytical Testing Weight Management CheckMate 67T Minoxidil Absorption SURMOUNT and SURPASS STEP Program Lecanemabe Progression-Free Survival STEP UP Trials MATTERHORN Trial Lenacapavir MONARCH 2 Trial MONARCH 3 Trial Asthma Exacerbations Semaglutide Trials Phase 2 Trials Weight Loss Drugs Acalabrutinib and Bendamustine-Rituximab DREAMM-8 Trial Long-term Data Antibody Response Weight Loss Medications SELECT Trial Results Pediatric Oncology CAPELLA Trial SUMMIT Trial Lecanemab Efficacy Lecanemab Trial Results Miplyffa Home Treatment Options Non-Inferiority Trials

FDA Approves Sotyktu for Active Psoriatic Arthritis as First TYK2 Inhibitor

The decision follows phase 3 POETYK trials showing clinically meaningful 16‑week responses with outcomes observed through one year.

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Stevia-Derived Microneedle Patch Boosts Minoxidil in Mouse Hair-Loss Study

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations